NCT04306224View on ClinicalTrials.gov

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Solid TumorLymphoma
Interventions
BIOLOGICAL

IMC-002

IMC-002 blocks the interaction between CD47 and SIRPα.

Trial Locations (4)

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

ImmuneOncia Therapeutics Inc.

INDUSTRY

NCT04306224 - A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | Biotech Hunter | Biotech Hunter